Skip to content

Study · Systematic review · n = 4,467 · 2025

14 results

Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis.

Cerchi E, Santo PADE, de Oliveira MC, Janovsky CCPS, Halpern B

International journal of obesity (2005)27 Sept 2025Cited by 2 (Europe PMC)

PMID41015578 (opens in a new tab)DOI10.1038/s41366-025-01920-4 (opens in a new tab)PepBankPUB-41015578
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults without diabetes, tirzepatide led to a greater relative weight reduction than placebo.

    In plain wordsIn adults without diabetes, tirzepatide led to a greater relative weight loss than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseRelative weight reduction in patients without diabetes
    Study

    n = 4,467

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5-15 mg once weekly · at least 26 weeksAs given in this study (human).

    Measurements

    relative weight reduction
    −17.15%
    without diabetes

    Source sentences

    Summary
    Compared with placebo, tirzepatide led to significantly greater relative and absolute weight reductions in patients with (RR -9.54%, p < 0.01; MD -9.06 kg, p < 0.01) and without diabetes (RR -17.15%, p < 0.01; MD -18.11 kg, p < 0.01).
    2 context sentences
    Summary · context
    We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks.
    Summary · context
    We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m2) and five (n = 4,467) in patients without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m2).
  2. 02HumanSystematic reviewEfficacy outcome

    In adults without diabetes, tirzepatide led to a greater absolute weight reduction than placebo.

    In plain wordsIn adults without diabetes, tirzepatide led to more weight loss in kilograms than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAbsolute weight reduction in patients without diabetes
    Study

    n = 4,467

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5-15 mg once weekly · at least 26 weeksAs given in this study (human).

    Measurements

    mean difference
    −18.11 kg
    without diabetes

    Source sentences

    Summary
    Compared with placebo, tirzepatide led to significantly greater relative and absolute weight reductions in patients with (RR -9.54%, p < 0.01; MD -9.06 kg, p < 0.01) and without diabetes (RR -17.15%, p < 0.01; MD -18.11 kg, p < 0.01).
    2 context sentences
    Summary · context
    We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks.
    Summary · context
    We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m2) and five (n = 4,467) in patients without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m2).
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with diabetes, tirzepatide led to a greater relative weight reduction than placebo.

    In plain wordsIn adults with diabetes, tirzepatide led to a greater relative weight loss than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseRelative weight reduction in patients with diabetes
    Study

    n = 2,174

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5-15 mg once weekly · at least 26 weeksAs given in this study (human).

    Measurements

    relative weight reduction
    −9.54%
    with diabetes

    Source sentences

    Summary
    Compared with placebo, tirzepatide led to significantly greater relative and absolute weight reductions in patients with (RR -9.54%, p < 0.01; MD -9.06 kg, p < 0.01) and without diabetes (RR -17.15%, p < 0.01; MD -18.11 kg, p < 0.01).
    2 context sentences
    Summary · context
    We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks.
    Summary · context
    We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m2) and five (n = 4,467) in patients without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m2).
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with diabetes, tirzepatide led to a greater absolute weight reduction than placebo.

    In plain wordsIn adults with diabetes, tirzepatide led to more weight loss in kilograms than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAbsolute weight reduction in patients with diabetes
    Study

    n = 2,174

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5-15 mg once weekly · at least 26 weeksAs given in this study (human).

    Measurements

    mean difference
    −9.06 kg
    with diabetes

    Source sentences

    Summary
    Compared with placebo, tirzepatide led to significantly greater relative and absolute weight reductions in patients with (RR -9.54%, p < 0.01; MD -9.06 kg, p < 0.01) and without diabetes (RR -17.15%, p < 0.01; MD -18.11 kg, p < 0.01).
    2 context sentences
    Summary · context
    We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks.
    Summary · context
    We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m2) and five (n = 4,467) in patients without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m2).
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with and without diabetes, tirzepatide increased the probability of achieving weight reduction of 5% or more versus placebo.

    In plain wordsIn adults with and without diabetes, tirzepatide made a weight loss of 5% or more more likely than placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreaseAchieving weight reduction of 5% or more
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5-15 mg once weekly · at least 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In both subpopulations, tirzepatide also significantly increased the probability of achieving weight reductions of ≥5%, ≥10%, and ≥15%
    2 context sentences
    Summary · context
    We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks.
    Summary · context
    We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m2) and five (n = 4,467) in patients without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m2).
  6. 06HumanSystematic reviewEfficacy outcome

    In adults with and without diabetes, tirzepatide increased the probability of achieving weight reduction of 10% or more versus placebo.

    In plain wordsIn adults with and without diabetes, tirzepatide made a weight loss of 10% or more more likely than placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreaseAchieving weight reduction of 10% or more
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5-15 mg once weekly · at least 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In both subpopulations, tirzepatide also significantly increased the probability of achieving weight reductions of ≥5%, ≥10%, and ≥15%
    2 context sentences
    Summary · context
    We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks.
    Summary · context
    We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m2) and five (n = 4,467) in patients without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m2).
  7. 07HumanSystematic reviewEfficacy outcome

    In adults with and without diabetes, tirzepatide increased the probability of achieving weight reduction of 15% or more versus placebo.

    In plain wordsIn adults with and without diabetes, tirzepatide made a weight loss of 15% or more more likely than placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreaseAchieving weight reduction of 15% or more
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5-15 mg once weekly · at least 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In both subpopulations, tirzepatide also significantly increased the probability of achieving weight reductions of ≥5%, ≥10%, and ≥15%
    2 context sentences
    Summary · context
    We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks.
    Summary · context
    We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m2) and five (n = 4,467) in patients without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m2).
  8. 08HumanSystematic reviewEfficacy outcome

    In adults with and without diabetes, tirzepatide improved BMI versus placebo.

    In plain wordsIn adults with and without diabetes, tirzepatide improved body mass index more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody mass index
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5-15 mg once weekly · at least 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In both subpopulations, tirzepatide also significantly increased the probability of achieving weight reductions of ≥5%, ≥10%, and ≥15%, as well as improved BMI, waist circumference, blood pressure, hemoglobin A1c, and lipid levels.
    2 context sentences
    Summary · context
    We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks.
    Summary · context
    We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m2) and five (n = 4,467) in patients without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m2).
  9. 09HumanSystematic reviewEfficacy outcome

    In adults with and without diabetes, tirzepatide improved waist circumference versus placebo.

    In plain wordsIn adults with and without diabetes, tirzepatide improved waist size more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWaist circumference
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5-15 mg once weekly · at least 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In both subpopulations, tirzepatide also significantly increased the probability of achieving weight reductions of ≥5%, ≥10%, and ≥15%, as well as improved BMI, waist circumference, blood pressure, hemoglobin A1c, and lipid levels.
    2 context sentences
    Summary · context
    We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks.
    Summary · context
    We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m2) and five (n = 4,467) in patients without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m2).
  10. 10HumanSystematic reviewEfficacy outcome

    In adults with and without diabetes, tirzepatide improved blood pressure versus placebo.

    In plain wordsIn adults with and without diabetes, tirzepatide improved blood pressure more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBlood pressure
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    5-15 mg once weekly · at least 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In both subpopulations, tirzepatide also significantly increased the probability of achieving weight reductions of ≥5%, ≥10%, and ≥15%, as well as improved BMI, waist circumference, blood pressure, hemoglobin A1c, and lipid levels.
    2 context sentences
    Summary · context
    We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks.
    Summary · context
    We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m2) and five (n = 4,467) in patients without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m2).
  11. 11HumanSystematic reviewEfficacy outcome

    In adults with and without diabetes, tirzepatide improved hemoglobin A1c versus placebo.

    In plain wordsIn adults with and without diabetes, tirzepatide improved hemoglobin A1c more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHemoglobin A1c
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5-15 mg once weekly · at least 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In both subpopulations, tirzepatide also significantly increased the probability of achieving weight reductions of ≥5%, ≥10%, and ≥15%, as well as improved BMI, waist circumference, blood pressure, hemoglobin A1c, and lipid levels.
    2 context sentences
    Summary · context
    We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks.
    Summary · context
    We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m2) and five (n = 4,467) in patients without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m2).
  12. 12HumanSystematic reviewEfficacy outcome

    In adults with and without diabetes, tirzepatide improved lipid levels versus placebo.

    In plain wordsIn adults with and without diabetes, tirzepatide improved blood fat levels more than placebo.

    Peptide
    Tirzepatide
    Outcome
    MixedLipid levels
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    5-15 mg once weekly · at least 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In both subpopulations, tirzepatide also significantly increased the probability of achieving weight reductions of ≥5%, ≥10%, and ≥15%, as well as improved BMI, waist circumference, blood pressure, hemoglobin A1c, and lipid levels.
    2 context sentences
    Summary · context
    We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks.
    Summary · context
    We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m2) and five (n = 4,467) in patients without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m2).
  13. 13HumanSystematic reviewEfficacy outcome

    Weight-related benefits with tirzepatide were significantly greater in patients without diabetes than in patients with diabetes.

    In plain wordsWeight-related benefits of tirzepatide were greater in people without diabetes than in people with diabetes.

    Peptide
    Tirzepatide
    Outcome
    Not applicableWeight-related benefit by diabetes status
    Study

    n: not reported in source

    Comparator
    Patients with diabetes
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5-15 mg once weekly · at least 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Notably, weight-related benefits with tirzepatide were significantly greater in patients without diabetes
    2 context sentences
    Summary · context
    We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks.
    Summary · context
    We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m2) and five (n = 4,467) in patients without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m2).
  14. 14HumanSystematic reviewSafety outcome

    Safety of tirzepatide was similar in patients with and without diabetes, mainly mild to moderate, well-tolerated adverse events.

    In plain wordsSafety of tirzepatide was similar in people with and without diabetes, mostly mild to moderate side effects that were well tolerated.

    Peptide
    Tirzepatide
    Outcome
    Not applicableSafety by diabetes status
    Study

    n: not reported in source

    Comparator
    Patients with diabetes
    Outcome group
    Adverse events · Whole body
    Studied dose
    5-15 mg once weekly · at least 26 weeksAs given in this study (human).

    Source sentences

    Summary
    whereas its safety was similar across subpopulations and predominantly consisted of mild to moderate, well-tolerated adverse events.
    2 context sentences
    Summary · context
    We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks.
    Summary · context
    We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m2) and five (n = 4,467) in patients without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m2).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.